La Jolla Pharmaceutical Company

NasdaqCM:LJPC 株式レポート

時価総額:US$155.1m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La Jolla Pharmaceutical 将来の成長

Future 基準チェック /46

La Jolla Pharmaceuticalは、59%と19.8%でそれぞれ年率59%で利益と収益が成長すると予測される一方、EPSはgrowで55.8%年率。

主要情報

59.0%

収益成長率

55.8%

EPS成長率

Biotechs 収益成長28.5%
収益成長率19.8%
将来の株主資本利益率n/a
アナリストカバレッジ

Low

最終更新日n/a

今後の成長に関する最新情報

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Recent updates

Innoviva to acquire La Jolla Pharma for $149M including debt

Jul 11

We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Nov 11
We Think La Jolla Pharmaceutical's (NASDAQ:LJPC) Robust Earnings Are Conservative

Our Take On La Jolla Pharmaceutical Company

Jul 02

La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue

May 07

La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Mar 11
La Jolla Pharmaceutical's (NASDAQ:LJPC) Shareholders Are Down 82% On Their Shares

Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Feb 11
Market Sentiment Around Loss-Making La Jolla Pharmaceutical Company (NASDAQ:LJPC)

Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

Jan 16
Industry Analysts Just Upgraded Their La Jolla Pharmaceutical Company (NASDAQ:LJPC) Revenue Forecasts By 18%

La Jolla Pharmaceutical rallies on exclusive licensing agreement with PAION

Jan 12

Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Jan 05
Should You Take Comfort From Insider Transactions At La Jolla Pharmaceutical Company (NASDAQ:LJPC)?

Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

Dec 09
Could The La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ownership Structure Tell Us Something Useful?

La Jolla Pharmaceutical EPS beats by $0.11, beats on revenue

Nov 09

業績と収益の成長予測

NasdaqCM:LJPC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20247716N/AN/A1
12/31/2023648N/AN/A1
12/31/2022471N/AN/A1
6/30/20224641313N/A
3/31/20225251414N/A
12/31/202176202828N/A
9/30/202174121818N/A
6/30/202170377N/A
3/31/202160-16-8-8N/A
12/31/202033-39-38-38N/A
9/30/202030-61-48-47N/A
6/30/202026-79-57-56N/A
3/31/202026-93-65-65N/A
12/31/201923-117-86-85N/A
9/30/201920-137-101-100N/A
6/30/201918-158-119-118N/A
3/31/201914-181-141-139N/A
12/31/201810-199-155-152N/A
9/30/20186-193-153-146N/A
6/30/20182-168-136-127N/A
3/31/20181-142-118-109N/A
12/31/2017N/A-115-94-85N/A
9/30/20170-101-83-78N/A
6/30/20170-96-78-75N/A
3/31/20170-85-70-68N/A
12/31/20161-78-61-59N/A
9/30/20161-65-50-49N/A
6/30/20162-54-40-39N/A
3/31/20161-49N/A-33N/A
12/31/20151-42N/A-25N/A
9/30/20151-37N/A-22N/A

アナリストによる今後の成長予測

収入対貯蓄率: LJPCの予測収益成長率 (年間59% ) は 貯蓄率 ( 1.9% ) を上回っています。

収益対市場: LJPCの収益 ( 59% ) はUS市場 ( 15.4% ) よりも速いペースで成長すると予測されています。

高成長収益: LJPCの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: LJPCの収益 ( 19.8% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: LJPCの収益 ( 19.8% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: LJPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘